Drug
Brolucizumab clinical trials
Also written RTH258, Beovu and ESBA1008.
- studies test it
- 35
- open now
- 0
- in phase 3
- 22
- first study started
- 2010
How studies write it
Studies that test it under each name
Brand
Studies by the year they started
35 studies that test it; most in 2019 (8)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2018 | 4 |
| 2019 | 8 |
| 2020 | 5 |
| 2021 | 6 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 4
- Phase 3
- 22
- Phase 4
- 7
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 7
Novartis Pharmaceuticals (22) · Alcon Research (6) · Benha University (2) · Berner Augenklinik (1) · The University of Hong Kong (1) · Vista Klinik (1) · Yeungnam University College of Medicine (1) · Faculty Hospital Kralovske Vinohrady (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses brolucizumab is read from its arms, and is right about nine times in ten.
Testing it · 35
- Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.CompletedPhase 4Novartis PharmaceuticalsNCT05959304Written as brolucizumab
- Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal VasculopathyCompletedPhase 3Novartis PharmaceuticalsNCT05666804Written as Brolucizumab 6mg
- Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMDActive, not recruitingNot applicableBerner AugenklinikNCT04932980Written as Brolucizumab
- Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic RetinopathyCompletedPhase 3Novartis PharmaceuticalsNCT04278417Written as Brolucizumab 6 mg
- Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationCompletedPhase 4Novartis PharmaceuticalsNCT04679935Written as Brolucizumab
- Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular EdemaCompletedNot applicableBenha UniversityNCT07096713Written as Intervention 1: Brolucizumab
- Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.CompletedPhase 4Novartis PharmaceuticalsNCT04774926Written as Brolucizumab
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 1CompletedPhase 3Alcon ResearchNCT02307682Written as Brolucizumab ophthalmic solution
- Efficacy and Safety of RTH258 Versus Aflibercept - Study 2CompletedPhase 3Alcon ResearchNCT02434328Written as Brolucizumab ophthalmic solution
- A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedPhase 3Novartis PharmaceuticalsNCT03481660Written as Brolucizumab
- Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular DegenerationCompletedPhase 3Novartis PharmaceuticalsNCT04047472Written as Brolucizumab 6mg
- Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular DegenerationCompletedPhase 3Novartis PharmaceuticalsNCT04264819Written as RTH258/Brolucizumab
- A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular DegenerationCompletedPhase 3Novartis PharmaceuticalsNCT04239027Written as RTH258/Brolucizumab
- To Compare Brolucizumab to Aflibercept in Chinese Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedPhase 3Novartis PharmaceuticalsNCT04058067Written as Brolucizumab
- An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) StudyCompletedPhase 3Novartis PharmaceuticalsNCT04597632Written as brolucizumab
- Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)CompletedPhase 3Novartis PharmaceuticalsNCT04005352Written as Brolucizumab 6 mg
- Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&ECompletedPhase 4The University of Hong KongNCT05710471Written as Brolucizumab
- Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaCompletedPhase 3Novartis PharmaceuticalsNCT03481634Written as Brolucizumab
- Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein OcclusionTerminatedPhase 3Novartis PharmaceuticalsNCT03802630Written as Brolucizumab 6 mg
- Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein OcclusionTerminatedPhase 3Novartis PharmaceuticalsNCT03810313Written as Brolucizumab 6 mg
Codes
What other systems call brolucizumab · ClinicalTrials.gg INT000767
- MeSH (NLM) C000622091brolucizumabOne source NLM
- UNII (FDA) XSZ53G39H5BROLUCIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2204915Confirmed FDA, Wikidata
- Wikidata Q25326694BrolucizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169818BrolucizumabOne source FDA
- DrugBank DB14864One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000622091 | brolucizumab | One source NLM |
| UNII (FDA) | XSZ53G39H5 | BROLUCIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2204915 | — | Confirmed FDA, Wikidata |
| Wikidata | Q25326694 | Brolucizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169818 | Brolucizumab | One source FDA |
| DrugBank | DB14864 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.